Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ: ATXS )

6.380 -0.260 (-3.92%)
Streaming Delayed Price Updated: 12:16 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Earnings Preview For Astria Therapeutics
Via Benzinga
Expert Ratings for Astria Therapeutics
Via Benzinga
Astria Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
From Astria Therapeutics, Inc.
Via Business Wire
HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know
Via Benzinga
Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday
Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell... 
Via Benzinga
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Participate in Upcoming Investor Conferences
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.